Last updated: July 27, 2026
ecutive summary
Actavis Elizabeth LLC v. Novartis Corporation (1:16-cv-00604) is a US patent litigation matter filed by Actavis against Novartis. The case is directly tied to Actavis’ generic development and includes patent infringement claims that are resolved through the Hatch-Waxman framework. No case-specific filing dates, asserted patent numbers, claim construction outcomes, settlement terms, or final judgment details are available in the information provided, so a litigation summary with actionable patent, exclusivity, or launch-risk conclusions cannot be produced.
Actavis Elizabeth LLC v. Novartis Corporation 1:16-cv-00604 litigation summary: What patents were asserted and what was the outcome?
Which Novartis patents did Actavis Elizabeth LLC challenge in 1:16-cv-00604?
Not available from provided inputs. A litigation summary requires the asserted patent list (publication/patent numbers, expiration data, and listed Orange Book patents tied to the reference product). None is provided.
Were the asserted patents method-of-use, formulation, or manufacturing patents?
Not available.
Were any patents asserted under Paragraph IV (ANDA context)?
Not available.
When was Actavis Elizabeth LLC vs. Novartis Corporation (1:16-cv-00604) filed and what procedural milestones occurred?
Not available from provided inputs. A complete summary requires docket milestones such as:
- Complaint filing date
- Answer deadline and any counterclaims
- Markman schedule and claim construction orders
- Motions to dismiss, summary judgment, or preliminary injunction briefing
- Trial dates or status conferences
- Dismissal/settlement timing
None is provided.
Did the case include an early resolution, consent judgment, or stipulated dismissal?
Not available.
What did the court decide in 1:16-cv-00604 (validity, infringement, or non-infringement)?
Not available from provided inputs. A litigation analysis must cite specific holdings or docket outcomes (e.g., “non-infringement,” “invalid,” “no injunction,” “case dismissed without prejudice,” or “final judgment entered”). No rulings are provided.
Were any patents found not infringed or held invalid?
Not available.
Was injunctive relief sought or granted?
Not available.
How did settlement affect patent enforcement for Actavis’ generic entry in 1:16-cv-00604?
Not available from provided inputs. Business-critical settlement terms include:
- Effective “launch at risk” date
- Carve-outs for design-arounds or additional strengths
- Payment-for-delay amounts (where applicable)
- Covenant not to sue scope
- Stipulated judgment terms
- Dates tied to patent expiration and/or exclusivity
None is provided.
Was there a stipulated dismissal following settlement?
Not available.
What does the Orange Book status for the reference product show for the patents at issue in 1:16-cv-00604?
Not available from provided inputs. Orange Book status requires:
- Listed patents tied to the specific NDA/BLA
- Patent expiration and any regulatory exclusivities
- Specific Orange Book listing numbers corresponding to the asserted patents
No reference product, NDA/BLA number, or Orange Book listing is provided.
Which parties besides Actavis and Novartis were involved in 1:16-cv-00604?
Not available from provided inputs. Patent litigation dockets often include additional Novartis entities and generic affiliates, and the specific names matter for covenant scope and enforcement risk.
How strong is the patent estate at issue based on what happened in court in 1:16-cv-00604?
Not available from provided inputs. Strength scoring depends on:
- Infringement and validity rulings
- Claim construction outcomes
- Court findings on prior art, enablement, written description, or obviousness
No judicial findings are provided.
What generic entry risks exist for Actavis or other ANDA filers based on 1:16-cv-00604?
Not available from provided inputs. Launch risk requires:
- Whether injunctions issued
- Whether patents were invalidated
- Settlement “carve-outs” that allow earlier market entry
- Remaining patents not asserted in the case but still listed in the Orange Book
None of these facts are provided.
How does Actavis Elizabeth LLC v. Novartis Corporation compare with similar Actavis-vs.-brand Hatch-Waxman cases?
Not available from provided inputs. A comparative analysis requires either:
- Other case docket outcomes with overlapping patents or same drug, or
- A specific pattern of settlements and court rulings with citations
Neither is provided.
Key Takeaways
- A litigation summary and analysis for Actavis Elizabeth LLC v. Novartis Corporation (1:16-cv-00604) cannot be completed without the asserted patent list, docket outcome, and procedural milestones.
- No patent expiration/exclusivity impact, settlement terms, or launch-risk conclusions can be derived from the provided information.
- Any business conclusions about generic timing, design-around feasibility, or enforcement remaining after the case would require case-specific holdings and/or settlement documents, which are not provided here.
FAQs
- What patents were listed in Orange Book for the reference product in Actavis Elizabeth LLC v. Novartis (1:16-cv-00604)?
- Did the court enter a preliminary injunction or bar generic launch in 1:16-cv-00604?
- Were any asserted claims construed in a way that narrowed the infringement scope in 1:16-cv-00604?
- Did the parties file a stipulated dismissal or consent judgment after settlement in 1:16-cv-00604?
- What remaining Novartis patents (not asserted in 1:16-cv-00604) could block launch after the case?
References
(No sources were provided in the prompt; no citations can be generated.)
